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The respiratory community is united in its desire to reduce and eliminate the harm caused by tobacco 
smoking, which is at present on course to kill one billion people in the 21st century. The stated policy of the 
European Respiratory Society is to strive “constantly to promote strong and evidence-based policies to reduce 
the burden of tobacco related diseases”. In our view, the recent ERS Tobacco Control Committee statement 
on tobacco harm reduction[1], though well-intentioned, appears to be based on a number of false premises 
and draws its conclusions from a partial account of available data. It also presents a false dichotomy between 
the provision of “conventional” tobacco control and harm reduction approaches. We therefore respond, in 
turn, to the seven arguments presented against the adoption of harm reduction in the Committee’s 
statement. 
1. The tobacco harm reduction strategy is based on incorrect claims that smokers cannot or will
not quit smoking.
The strategy is in fact based on the need for additional measures to help the estimated 100 million smokers 
in the European Union who still have not quit. Europe has the highest smoking prevalence of all the WHO 
Regions[2] and business as usual has so far failed to help these individuals. Smoking rates are significantly 
associated with economic disadvantage and ongoing failure to address this is a huge driver of health 
inequality.  
2. The tobacco harm reduction strategy is based on undocumented assumptions that alternative nicotine 
delivery products are highly effective as a smoking cessation aid.
When smokers use a nicotine replacement product to substitute for cigarettes, even in the absence of 
intention to quit, they are approximately twice as likely to proceed to quit smoking completely[3]. It would 
be astonishing if nicotine delivered via e-cigarettes was uniquely ineffective in helping people to quit 
smoking. In fact, in a definitive head-to-head randomised controlled clinical trial, electronic cigarettes proved 
to be twice as effective as combination nicotine replacement therapy (NRT) when delivered as part of an 





























































evidence-based smoking cessation intervention[4] and in a recently published smaller New Zealand trial, four 
times more effective than nicotine patches alone[5]. Whether e-cigarettes are “highly effective” is a question 
of definition, but it is not an “undocumented assertion” to observe that they are certainly at least as effective 
as medicinal NRT[4, 5] . 
3. The tobacco harm reduction strategy is based on incorrect assumptions that smokers will replace 
conventional cigarettes with alternative nicotine delivery products.
Harm reduction strategies do not assume that all smokers will completely switch from tobacco cigarettes to 
alternative products, any more than does the medicinally licensed strategy of using nicotine replacement 
therapy to cut down on smoking. The strategy is instead based on an initial expectation, subsequently 
supported by clear empirical evidence[6, 7], that an appreciable proportion will switch. 
4. The tobacco harm reduction strategy is based on undocumented assumptions that alternative nicotine 
delivery products are generally harmless.
No credible commentator has argued that reduced harm products are harmless. By definition, harm 
reduction strategies are based on reducing rather than eliminating harm and the likelihood that there is some 
risk from their long term use is explicitly acknowledged in statements on the subject[8-11]. However, the fact 
that many of the elements found in tobacco smoke that are known to cause toxicity are either absent from 
e-cigarette vapour or present at much lower levels[12] does support a substantial reduction in this risk. 
Supportive clinical data in smokers who switch to vaping include rapid improvement in vascular endothelial 
function[13], profound falls in systemic carcinogen levels to ones equivalent to ex-smokers using NRT[14] 
and improvement in respiratory symptoms[4]. Understandable concerns over safety arising from the 2019 
outbreak of vaping-related lung injury (EVALI) in the US have been alleviated by evidence it was caused by 
vaping illicit products, in particular THC cut with vitamin E acetate[15]. 





























































5. Alternative nicotine delivery products can have a negative impact on public health even if “stick-by-stick” 
they turn out to be less harmful than conventional cigarettes. 
The argument this statement introduces is that e-cigarettes are driving increasing numbers of young people 
to become nicotine addicted and to go on to become smokers. In fact experimentation with e-cigarettes 
occurs predominantly among young people who have already started smoking or are at increased risk of 
smoking[16, 17], thus representing a rational choice over the far more hazardous tobacco product. Most 
importantly, smoking rates among teenagers in the US and UK are falling [18-22].  The same is true of adult 
smoking, which is falling in both countries[23, 24], particularly rapidly in the UK as increasing numbers of 
adult smokers switch to e-cigarettes[24]. Moreover, parental smoking is one of the main drivers of child 
smoking uptake[22], so as e-cigarette use enables more adults to quit so fewer children will have smoking 
parents as role models and more children will be protected from in utero and passive smoke exposure.
6. Smokers see alternative nicotine delivery products as a viable alternative to the use of evidence-based 
smoking cessation services and smoking cessation pharmacotherapy
Smokers are correct to view e-cigarettes as a viable, evidence-based and proven option to aid smoking 
cessation[4, 5] and the development of novel approaches for people who have tried conventional 
pharmacotherapy unsuccessfully should be welcomed. It is also incorrect to regard e-cigarettes as an 
alternative to engaging with smoking cessation services, given the compelling evidence that combining 
psychological support with nicotine replacement increases quit rates. It is precisely the exclusion of people 
who are choosing to try to quit smoking using e-cigarettes that is likely to reduce these individuals’ chances 
of success. Most importantly, although the Statement argues that smoking cessation services “exist”, in 
practice provision of smoking cessation services is limited[25, 26], more so given political choices to pursue 
austerity policies which reduce public health funding. Access to such services may therefore be difficult, 
especially for the most disadvantaged people and those with disorganised lives. Rejection of harm reduction 
strategies is thus likely to worsen health inequalities.





























































7. The tobacco harm reduction strategy is based on incorrect claims that we cannot curb the tobacco 
epidemic.
Harm reduction complements conventional tobacco control strategies, it does not replace them. The UK 
leads Europe in implementing tobacco control policies, including the exclusion of the tobacco industry from 
influence on policy making[27] and smoking rates there have declined faster than the rest of Europe as a 
result[28]. Combined with a rational and regulated approach to electronic cigarettes [Table 1] the UK is now 
experiencing rates of decline in smoking prevalence - from 20.2 in 2011 to 14.7% in 2018 - faster than for 
decades[24] and in England the ambition is to reduce smoking prevalence to below 5% across all groups by 
2030. European countries in general, and the ERS in particular, should take heed of this evidence, rather than 
ignore it. 
We believe that blanket opposition to e-cigarettes is misguided and will lead to a number of important 
consequences that are adverse to health. First, smokers who would otherwise have quit smoking by switching 
to a lower risk product will continue to smoke, and die prematurely from cancer, cardiovascular and 
respiratory disease. Second, people who have successfully switched to vaping may relapse to smoking if they 
come to believe that there is no health benefit from vaping, and thus increase their risk of avoidable 
morbidity and premature death. Third, the pursuit of arguments that vaping can’t help people to quit 
smoking, in the face of clear evidence that it does, risks undermining public trust in science. 
We wholeheartedly support the call for increased efforts to deliver “what we know works”. E-cigarette use 
is an epiphenomenon of smoking and current smoking levels are a consequence of past failures and delays 
in the implementation of tobacco control measures including effective and accessible treatment, tax 
increases, smokefree legislation, advertising bans and public health campaigns[29]. We respectfully suggest 
that the Society reconsiders its position, so that we can focus on our shared goal to make smoking history.





























































TABLE 1   Key messages for a rational approach to vaping and e-cigarettes
1 People smoke tobacco because of nicotine addiction, but the major harms come not from the nicotine 
but from toxic substances in the smoke.
2 Pharmacotherapy (e.g. dual NRT or varenicline) combined with psychological support should be made 
available to all smokers to help them to quit and should be considered as the first line approach.
3 E-cigarettes are an effective means to deliver nicotine, with a much lower risk of harm than continuing 
to smoke.
4 People who choose to use e-cigarettes to cut down or quit smoking should be offered psychological 
support and access to smoking cessation services. 
5 People who choose to use e-cigarettes should be advised that they need to switch completely in order 
to derive substantial health benefits.
6 People using e-cigarettes should be advised to try to quit them too in the long term, but not at the 
risk of relapsing to smoking.
7 Never-smokers should avoid e-cigarettes.
8 E-cigarettes should continue to be subject to restrictions on age of sale, on advertising and on the 
strength of e-liquids, as set out in the EU Tobacco Products Directive.
9 Respiratory clinicians must continue to campaign for the full implementation of the WHO MPOWER 
strategy[30] designed to assist implementation of the Framework Convention on Tobacco Control, as 
this is the most powerful tool to deliver a smokefree generation.
 Monitor tobacco use and prevention policies
 Protect people from tobacco smoke
 Offer help to quit tobacco use
 Warn about the dangers of tobacco use
 Enforce bans on tobacco advertising, promotion and sponsorship
 Raise taxes on tobacco
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